POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF TUMOR SHRINKAGE BY AXITINIB IN PATIENTS WITH RENAL CELL CARCINOMA.

被引：0
|
作者：
Chen, Y. [1 ]
Houk, B. A. [1 ]
Ruiz, A. [1 ]
Bair, A. A. [1 ]
Pithavala, Y. K. [1 ]
机构：
[1] Pfizer, San Diego, CA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2014年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [1] Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis
    Rini, Brian I.
    Garrett, May
    Poland, Bill
    Dutcher, Janice P.
    Rixe, Olivier
    Wilding, George
    Stadler, Walter M.
    Pithavala, Yazdi K.
    Kim, Sinil
    Tarazi, Jamal
    Motzer, Robert J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (05): : 491 - 504
  • [2] Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
    Reza Khosravan
    Robert J. Motzer
    Elena Fumagalli
    Brian I. Rini
    Clinical Pharmacokinetics, 2016, 55 : 1251 - 1269
  • [3] Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
    Khosravan, Reza
    Motzer, Robert J.
    Fumagalli, Elena
    Rini, Brian I.
    CLINICAL PHARMACOKINETICS, 2016, 55 (10) : 1251 - 1269
  • [4] POPULATION PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF SUNITINIB (SU) IN GASTROINTESTINAL STROMAL TUMOR (GIST) AND RENAL CELL CARCINOMA (RCC) PATIENTS
    Khosravan, R.
    Mugundu, G. M.
    Casali, P. G.
    Rini, B. I.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S76 - S77
  • [5] Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients
    Jian-Feng Lu
    Laurent Claret
    Liviawati Sutjandra
    Mita Kuchimanchi
    Rebeca Melara
    René Bruno
    Yu-Nien Sun
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 1151 - 1158
  • [6] Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients
    Lu, Jian-Feng
    Claret, Laurent
    Sutjandra, Liviawati
    Kuchimanchi, Mita
    Melara, Rebeca
    Bruno, Rene
    Sun, Yu-Nien
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (06) : 1151 - 1158
  • [7] Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma.
    Anandappa, G.
    Sala, E.
    Cheow, H. K.
    Bird, N. J.
    Shaw, A.
    Priest, A. N.
    Gill, A.
    Fryer, T.
    Hong, Y. T.
    Smith, R.
    Backen, A.
    Whitcher, B.
    Jonson, A.
    Richards, D.
    Cookson, L.
    Lee, W. M. F.
    Dive, C.
    Fife, K. M.
    Jodrell, D. I.
    Eisen, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
    Tsimafeyeu, Ilya
    Borisov, Pavel
    Abdelgafur, Ahmed
    Leonenkov, Roman
    Novikova, Olga
    Guseva, Irina
    Demchenkova, Marina
    Mikhailova, Nadezhda
    Semenov, Andrey
    Yurmazov, Zakhar
    Sivunova, Irina
    Ramazanova, Madina
    Gamayunov, Sergey
    Kosov, Dmitry
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma
    Ying Chen
    Brian I. Rini
    Angel H. Bair
    Ganesh M. Mugundu
    Yazdi K. Pithavala
    Clinical Pharmacokinetics, 2015, 54 : 397 - 407
  • [10] Population Pharmacokinetic-Pharmacodynamic Modelling of 24-h Diastolic Ambulatory Blood Pressure Changes Mediated by Axitinib in Patients with Metastatic Renal Cell Carcinoma
    Chen, Ying
    Rini, Brian I.
    Bair, Angel H.
    Mugundu, Ganesh M.
    Pithavala, Yazdi K.
    CLINICAL PHARMACOKINETICS, 2015, 54 (04) : 397 - 407
12345